Keyword: Teva Pharmaceutical
Teva rolled out its global rebrand in Canada focusing on its research that found that almost 40% of Canadians self-identify as caregivers.
Teva agreed to a $54 million settlement to resolve whistleblower allegations it paid kickbacks to boost scripts for Copaxone and Azilect.
Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.
Already facing thousands of civil suits, Johnson & Johnson and Teva could be facing a criminal investigation into their opioid businesses.
Teva and other generic companies have been engaged in settlement talks with federal prosecutors for the last 6 months, Bloomberg reports.
Teva Pharmaceuticals is having issues with its API plant in Italy serious enough that it has had to stop production.
Teva will produce its new migraine drug at a plant in Israel and more news of note.
Teva is riding high after a strong launch for Austedo. But is "tenfold" patient growth in one of its indications possible? Analysts aren't so sure.
In 2015, Teva beat out the competition and scored a $2.3 billion buyout of Mexican generics firm Rimsa. In the long run, though, it wasn’t a win.